Primary immunodeficiencies are rare immunologic diseases whose main characteristics are recurrent infections. These diseases are frequently unsuspected and the delayed diagnosis makes complications irreversible with the consequent poor quality of life. In Mexico, primary immunodeficiencies have a low prevalence, which is secondary to under-diagnosis and the lack of specialized laboratory studies in most hospitals. Since there is a registration of primary immunodeficiency cases in Europe and other developed countries, it is possible to estimate the incidence of primary immunodeficiencies and to elaborate guidelines of diagnosis and treatment. In our country we do not have any epidemiological registry; however, from 1998 to 2004 the number of cases of primary immunodeficiency has increased; the minimal incidence calculated is 0.16 to 0.24 per 100,000 births for chronic granulomatous disease, severe combined immunodeficiency and X linked agammaglobulinemia, this data is still very low compared to other international registries. We present an epidemiological review of primary immunodeficiency prevalence in Mexico compared to some international reports.
Download full-text PDF |
Source |
---|
Leuk Lymphoma
January 2025
School of Clinical Sciences at Monash Health, Lymphoma Research Group, Monash University, Clayton, Australia.
Over the past two decades, there has been a continuous improvement in outcome for patients with indolent lymphoma (iNHL) resulting in a gradual accumulation of survivors. While life expectancy in the current era approaches that of the lymphoma-free population, patients continue to experience lifelong complications of the disease and its treatment affecting general health, emotional, psychological and social wellbeing, relationships, employment, finances, and fitness. Contemporary care models while suited to the management of lymphoma are often lacking when it comes to identification and management of these additional needs.
View Article and Find Full Text PDFObjective: Aim: To investigate the effect of succinic acid on the humoral component of the immune system in rats.
Patients And Methods: Materials and Methods: The study was conducted on two groups of mature non-linear white rats (males) of similar weight (200-270 g, aged 6-8 months), with 5 animals in each group. The control group was fed a standard diet with free access to water throughout the experiment.
Front Immunol
January 2025
Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
Activated PI3K delta syndrome (APDS) is a primary immunodeficiency that is caused by mutations in the PI3K signalling pathway resulting in either gain-of-function or loss-of-function phenotypes of APDS 1 and 2. Malignancy is one of the most serious complications associated with APDS patients, with the most commonly occurring of these being lymphoma, and is the most common cause of death in APDS patients. Management of APDS is complex and variable due to the heterogeneous nature of the disease and ranges from antimicrobial and immunosuppressant agents to haematopoetic stem cell transplantation.
View Article and Find Full Text PDFBMC Health Serv Res
January 2025
Sydani Initiative for International Development, FCT, Abuja, Nigeria.
Background: Evidence from literature has established that tracing lost to follow-up clients is an effective strategy for complementing other mechanisms for infectious disease control like human immunodeficiency virus (HIV), tuberculosis, and other diseases such as Ebola. As a long-standing successful public health method of optimizing acceptance and/or adherence to infectious disease treatment tracing lost to follow-up clients is usually carried out by manually investigating individuals who absconded or are absent from treatments designed to manage and/or promote their health status. This study seeks to explore the role of mobile teams in tracing clients lost to follow-up for immunization.
View Article and Find Full Text PDFActa Neurol Belg
January 2025
Department of Radiology, CHU UCL Namur site Godinne, Université catholique de Louvain, Avenue G. Thérasse 1, Yvoir, 5530, Belgium.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!